Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Minority Interest (2018 - 2021)

Sangamo Therapeutics has reported Minority Interest over the past 4 years, most recently at -$938000.0 for Q1 2021.

  • Quarterly results put Minority Interest at -$938000.0 for Q1 2021, down 856.45% from a year ago — trailing twelve months through Mar 2021 was -$938000.0 (down 856.45% YoY), and the annual figure for FY2020 was -$868000.0, down 569.19%.
  • Minority Interest for Q1 2021 was -$938000.0 at Sangamo Therapeutics, down from -$868000.0 in the prior quarter.
  • Over the last five years, Minority Interest for SGMO hit a ceiling of $739000.0 in Q4 2018 and a floor of -$938000.0 in Q1 2021.
  • Median Minority Interest over the past 4 years was $154500.0 (2019), compared with a mean of $0.0.
  • Biggest five-year swings in Minority Interest: tumbled 74.97% in 2019 and later plummeted 856.45% in 2021.
  • Sangamo Therapeutics' Minority Interest stood at $739000.0 in 2018, then tumbled by 74.97% to $185000.0 in 2019, then crashed by 569.19% to -$868000.0 in 2020, then dropped by 8.06% to -$938000.0 in 2021.
  • The last three reported values for Minority Interest were -$938000.0 (Q1 2021), -$868000.0 (Q4 2020), and -$530000.0 (Q3 2020) per Business Quant data.